Pharmacology Biochemistry and Behavior, Journal Year: 2019, Volume and Issue: 180, P. 60 - 73
Published: March 25, 2019
Language: Английский
Annual Review of Psychology, Journal Year: 2020, Volume and Issue: 71(1), P. 79 - 106
Published: Jan. 4, 2020
Addiction is commonly identified with habitual nonmedical self-administration of drugs. It usually defined by characteristics intoxication or withdrawal symptoms. Such addictions can also be in terms the brain mechanisms they activate; most addictive drugs cause elevations extracellular levels neurotransmitter dopamine. Animals unable to synthesize use dopamine lack conditioned reflexes discussed Pavlov appetitive behavior Craig; have only unconditioned consummatory reflexes. Burst discharges (phasic firing) dopamine-containing neurons are necessary establish long-term memories associating predictive stimuli rewards and punishers. Independent (tonic pacemaker determine motivation respond such cues. As a result intake drugs, receptors expressed decreased, thereby reducing interest activities not already stamped rewards.
Language: Английский
Citations
305
Pharmacological Research, Journal Year: 2025, Volume and Issue: 213, P. 107657 - 107657
Published: Feb. 19, 2025
Research carried out during the last 30 years since first identification of CB2r in 1993 has changed landscape this receptor's role and therapeutic utility. Initially, studies focused on elucidating at periphery it was characterized spleen lymphocytes. Later, found brain not only under pathological conditions but also basal conditions. It is now known that receptor expressed different regions cell types, including neurons microglia. Experimental have provided robust evidence involved modulation immune system, neuroinflammation, oxidative stress neuroprotection. Besides, mediated response to stress, anxiety, depression. Also, plays a relevant modulating reinforcing properties drugs abuse, alcohol, nicotine cocaine. In review, we summarize cumulative knowledge regarding immunomodulatory, anti-inflammatory, antioxidant, neuroprotective against development neurodegenerative diseases. Indeed, cover anxiolytic antidepressant potential CB2r, which raises interest psychiatric diseases associated with anxiety Finally, discuss involvement regulation drug addiction. A better understanding essential for pharmacological neurodegenerative, psychiatric, addictive disorders.
Language: Английский
Citations
3
Neuropharmacology, Journal Year: 2019, Volume and Issue: 167, P. 107740 - 107740
Published: Aug. 19, 2019
Language: Английский
Citations
106
Physiology & Behavior, Journal Year: 2019, Volume and Issue: 202, P. 62 - 68
Published: Jan. 31, 2019
Language: Английский
Citations
96
Dialogues in Clinical Neuroscience, Journal Year: 2020, Volume and Issue: 22(3), P. 241 - 250
Published: Sept. 30, 2020
The last decades have seen a major gain in understanding the action of cannabinoids and endocannabinoid system reward processing development addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol synthetic directly interact with thereby properties. Cannabinoids induce their reinforcing properties by an increase tonic dopamine levels through cannabinoid type 1 (CB1) receptor–dependent mechanism within ventral tegmental area. Cues that are conditioned to cannabis smoking can drug-seeking responses (ie, craving) eliciting phasic events. A dopamine-independent involved involves endocannabinoid/glutamate interaction corticostriatal part system. In conclusion, pharmacological blockade signaling should lead reduction drug craving subsequently reduce relapse behavior addicted individuals. Indeed, there is increasing preclinical evidence targeting reduces relapse, allosteric modulators at CB1 receptors fatty acid amide hydrolase inhibitors clinical for use disorder. Cannabidiol, which mainly acts on CB2 receptors, currently being tested patients alcohol disorder opioid
Language: Английский
Citations
90
Frontiers in Pharmacology, Journal Year: 2021, Volume and Issue: 12
Published: May 20, 2021
Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack approved or alarming relapse rates. These facts hamper clinical outcome and quality life patients supporting importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant neurological such as epilepsy, sclerosis, Parkinson's, Alzheimer's diseases. Furthermore, there is a large body evidence pointing out CBD improves cognition, neurogenesis anxiolytic, antidepressant, antipsychotic, neuroprotective suggesting potential usefulness treatment neuropsychiatric diseases SUD. Here we review preclinical regarding on regulation reinforcing, motivational withdrawal-related different drugs abuse alcohol, opioids (morphine, heroin), cannabinoids, nicotine, psychostimulants (cocaine, amphetamine). special section focused neurobiological mechanisms might be underlying 'anti-addictive' action through dopaminergic, opioidergic, serotonergic, endocannabinoid systems well hippocampal neurogenesis. The multimodal profile described specific addictive behavior-related targets explains, at least part, its therapeutic reinforcing properties abuse. Moreover, remarkable safety CBD, existence medications containing this compound (Sativex®, Epidiolex®) increased number studies intervention rising publications with substantial results valuable innovation treating SUD, undeniable need agents improve upcoming trials involving endorse relevance review.
Language: Английский
Citations
59
International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(2), P. 975 - 975
Published: Jan. 17, 2022
The endocannabinoid system (ECS) is ubiquitous in most human tissues, and involved the regulation of mental health. Consequently, its dysregulation associated with neuropsychiatric neurodegenerative disorders. Together, ECS expanded endocannabinoidome (eCBome) are composed genes coding for CB1 CB2 cannabinoid receptors (CB1R, CB2R), endocannabinoids (eCBs), metabolic enzyme machinery their synthesis catabolism. activation CB1R adverse effects on central nervous (CNS), which has limited therapeutic use drugs that bind this receptor. discovery functional neuronal CB2R raised new possibilities potential safe targeting treatment CNS Previous studies were not able to detect mRNA transcripts brain tissue suggested CB2Rs absent considered peripheral receptors. Studies done role as a target treating different disorders revealed important putative certain disorders, requires further clinical validation. This review addresses recent advances including, but to, anxiety, depression, schizophrenia, Parkinson’s disease (PD), Alzheimer’s (AD), Huntington’s (HD) addiction.
Language: Английский
Citations
45
Pharmacopsychiatry, Journal Year: 2024, Volume and Issue: 57(03), P. 115 - 132
Published: Jan. 24, 2024
Abstract The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), naturally occurring cannabinoid, has been investigated in several conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited most indications. This review comprises comprehensive literature search identify studies on CBD included case studies, reports, observational RCTs published English before July 27, 2023, excluding involving nabiximols or cannabis extracts containing ∆9-tetrahydrocannabinol. Completed were considered, all authors independently assessed relevant publications. Of 150 articles identified, 54 publications included, covering healthy subjects various such schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress disorder (PTSD), autism spectrum disorders. No have other potential indications, alcohol disorder, borderline personality depression, dementia, attention-deficit/hyperactivity disorder. critical highlights that can potentially ameliorate certain including SUDs, PTSD. However, more controlled trials, particularly investigating mid- long-term CBD, are required conclusively establish its efficacy these complex neural activity patterns, likely by impacting system, warrant further research reveal therapeutic psychiatry.
Language: Английский
Citations
13
European Neuropsychopharmacology, Journal Year: 2020, Volume and Issue: 36, P. 191 - 205
Published: Feb. 1, 2020
Language: Английский
Citations
64
Inflammopharmacology, Journal Year: 2022, Volume and Issue: 30(4), P. 1167 - 1178
Published: July 7, 2022
Combination tetrahydrocannabinol (THC)/cannabidiol (CBD) medicines or CBD-only are prospective treatments for chronic pain, stress, anxiety, depression, and insomnia. THC CBD increase signaling from cannabinoid receptors, which reduces synaptic transmission in parts of the central peripheral nervous systems secretion inflammatory factors immune glial cells. The overall effect adding to is enhance analgesic but counteract some adverse effects. There substantial evidence effectiveness THC/CBD combination especially neuropathic nociplastic pain with an component. For medication, there moderate anxiety insomnia, minimal depression pain. have a good tolerability safety profile relative opioid analgesics negligible dependence abuse potential; however, should be avoided patients predisposed psychosis suicide as these conditions appear exacerbated. Non-serious events usually dose-proportional, subject tachyphylaxis rarely dose limiting when commenced on low gradual up-titration. inhibit several Phase I II metabolism enzymes, increases exposure wide range drugs appropriate care needs taken. Low-dose that appears effective mental health has safety, few effects initial treatment.
Language: Английский
Citations
31